Acute Viral Hepatitis (ICD-11: 1E50) - Complete Clinical Coding Guide
1. Introduction
Acute viral hepatitis represents an important global public health problem, characterized as an inflammatory process of the liver caused by viral infection of sudden onset. This condition affects millions of people annually and can range from asymptomatic or mild forms to severe presentations with risk of fulminant hepatic failure. The main etiological agents include hepatitis A, B, C, D, and E viruses, each with distinct epidemiological characteristics, modes of transmission, and prognoses.
The clinical importance of acute viral hepatitis lies not only in its immediate manifestations, but also in the potential for progression to chronic forms, particularly in cases of hepatitis B and C. The acute phase represents a critical window for therapeutic intervention and adoption of preventive measures to avoid additional transmission. Early recognition and appropriate management can prevent serious complications, including hepatic failure, need for transplantation, and death.
Precise coding of acute viral hepatitis is fundamental for epidemiological surveillance, health policy planning, resource allocation, clinical research, and appropriate management of health systems. The transition to ICD-11 brought greater specificity and clarity in the classification of viral hepatitis, allowing better differentiation between acute and chronic forms, as well as between different etiological agents. Healthcare professionals, coders, and managers must understand the nuances of this code to ensure reliable epidemiological data and appropriate continuity of patient care.
2. Correct ICD-11 Code
Code: 1E50
Description: Acute viral hepatitis
Parent category: Viral hepatitis
The code 1E50 in ICD-11 specifically designates cases of viral hepatitis in its acute phase, characterized by hepatic inflammation of recent onset caused by hepatotropic viruses. This code encompasses all forms of acute viral hepatitis, regardless of the specific etiologic agent (virus A, B, C, D, or E), when the clinical and laboratory presentation indicates an acute inflammatory process of the hepatic parenchyma.
It is important to note that the official definition provided in the system appears to contain an inconsistency, as it describes characteristics typical of chronic hepatitis (infection lasting more than 6 months, fibrosis, cirrhosis), when code 1E50 specifically refers to the acute form. Acute viral hepatitis proper is characterized by a picture of sudden or subacute onset, with duration less than six months, presenting symptoms such as fatigue, jaundice, nausea, vomiting, abdominal pain, dark urine, and acholic stools.
The diagnosis of acute viral hepatitis is based on the combination of clinical manifestations, elevation of hepatic enzymes (transaminases frequently more than 10 times the upper limit of normal) and detection of specific serologic markers: anti-HAV IgM for hepatitis A, HBsAg and anti-HBc IgM for hepatitis B, anti-HCV for hepatitis C (with detectable HCV-RNA), anti-HDV for hepatitis D, and anti-HEV IgM for hepatitis E. Adequate documentation of these criteria is essential for correct coding.
3. When to Use This Code
The code 1E50 should be used in specific clinical scenarios that characterize acute viral hepatitis:
Scenario 1: Patient with sudden onset jaundice and positive viral markers A previously healthy patient presents with a one-week clinical course characterized by jaundice, dark urine, acholic stools, intense fatigue, and nausea. Laboratory tests reveal ALT of 1,200 U/L, AST of 980 U/L, total bilirubin of 8.5 mg/dL (predominantly direct) and positive serology for anti-HAV IgM. This is a classic example of acute hepatitis A, which should be coded as 1E50.
Scenario 2: Occupational exposure with seroconversion A healthcare professional sustains an accident with contaminated sharp material. After four weeks, constitutional symptoms develop, elevation of transaminases (ALT 850 U/L), and serological tests demonstrate positive HBsAg and reactive anti-HBc IgM, confirming acute hepatitis B. The code 1E50 is appropriate in this context of documented acute infection.
Scenario 3: Traveler returning from endemic area An individual returns from travel to a region with poor sanitary conditions and, two weeks after returning, presents with fever, malaise, abdominal pain, and jaundice. Laboratory investigation shows marked elevation of transaminases and positive anti-HEV IgM, characterizing acute hepatitis E. The correct coding is 1E50.
Scenario 4: Acute hepatitis in injectable drug user A patient with a history of intravenous drug use presents with acute hepatitis with ALT of 1,500 U/L. Serology reveals positive HBsAg, positive anti-HBc IgM, and reactive anti-HDV, indicating acute coinfection with virus B and D. Both infections are in the acute phase, justifying the use of code 1E50.
Scenario 5: Fulminant hepatitis with acute liver failure A patient develops severe acute viral hepatitis with rapid progression to hepatic encephalopathy and coagulopathy in the context of acute hepatitis B virus infection. Although there is liver failure, the primary etiology is acute viral hepatitis, and 1E50 should be used as the principal diagnosis, with an additional code for liver failure if applicable.
Scenario 6: Viral reactivation interpreted as new acute episode A patient with known chronic hepatitis B presents with acute exacerbation with significant elevation of transaminases and symptoms of acute hepatitis. In this case, although there is acute manifestation, the underlying diagnosis is chronic hepatitis, and code 1E50 would generally not be appropriate, and the code for chronic hepatitis with exacerbation specifier should be used, if available.
4. When NOT to Use This Code
Appropriate coding requires clarity about situations in which code 1E50 should not be applied:
Established chronic viral hepatitis: Patients with persistent viral infection for more than six months, even if asymptomatic or with normal liver enzymes, should be coded as chronic viral hepatitis (1E51), not acute. The temporal distinction is fundamental: acute refers to infections with less than six months duration.
Acute or subacute liver failure of other etiology: When liver failure is not caused primarily by acute viral infection, but rather by medication toxicity, autoimmune hepatitis, Wilson disease, or other causes, specific codes for these conditions should be used. Code 1E50 is reserved for cases where acute viral etiology is confirmed.
Non-viral infectious liver disease: Liver infections caused by bacteria, parasites, or fungi (such as pyogenic liver abscess, hepatic schistosomiasis, or hepatic candidiasis) should not be coded as 1E50. These conditions have specific codes within the category of infectious liver diseases.
Asymptomatic carriers: Individuals with positive serological markers (such as HBsAg) but without evidence of active liver inflammation, normal enzymes, and without symptoms do not have acute hepatitis. These cases should be coded as viral carrier state, not acute hepatitis.
Drug-induced or toxic hepatitis: Even if the clinical presentation is similar to acute viral hepatitis, when the cause is medication-related, alcoholic, or from other toxins, specific codes for toxic hepatitis should be used. The etiological distinction is crucial for correct coding.
Reactivation of chronic hepatitis: Patients with known chronic hepatitis B or C who present with acute exacerbation (flare) should be coded as chronic hepatitis, not acute, since the underlying infection is chronic. The presence of acute symptoms does not transform chronic hepatitis into acute.
5. Step-by-Step Coding Process
Step 1: Assess diagnostic criteria
The first essential step is to confirm the diagnosis of acute viral hepatitis through a combination of clinical, laboratory, and serological criteria. Clinically, there must be evidence of acute hepatic syndrome: recent onset (days to weeks) of symptoms such as jaundice, fatigue, nausea, vomiting, abdominal pain in the right upper quadrant, dark urine, and/or acholic stools. Some patients may be asymptomatic or oligosymptomatic.
Laboratory findings must show significant elevation of aminotransferases (ALT and AST), typically above 10 times the upper limit of normal in the acute phase, although lower values do not exclude the diagnosis. Elevation of bilirubin (mainly direct) usually accompanies icteric cases. Liver function tests (prothrombin time, albumin) should be evaluated to determine severity.
Serological confirmation is mandatory: anti-HAV IgM for hepatitis A, HBsAg with anti-HBc IgM for acute hepatitis B, detection of HCV RNA in patients with recent exposure for acute hepatitis C, anti-HDV in the context of hepatitis B for hepatitis D, and anti-HEV IgM for hepatitis E. Documentation of these markers is fundamental for appropriate coding.
Step 2: Verify specifiers
After confirming the diagnosis, it is necessary to evaluate specific characteristics that may require additional or more detailed coding. Severity must be determined: mild (minimal symptoms, elevated transaminases but preserved liver function), moderate (significant symptoms but without liver failure) or severe (with signs of liver failure such as coagulopathy, encephalopathy).
Duration of illness must be documented to confirm that it is in the acute phase (less than six months from onset). The specific etiological agent, when identified, may require a more specific code within category 1E50. Complications such as acute liver failure, prolonged cholestasis, or extrahepatic manifestations should be identified and may require complementary coding.
Step 3: Differentiate from other codes
The main differentiation must be made with code 1E51 (Chronic viral hepatitis). The fundamental distinction is temporal: acute hepatitis has a duration of less than six months from the onset of infection, while chronic hepatitis persists for six months or longer. Furthermore, serological markers differ: in acute hepatitis, IgM antibodies and markers of recent infection predominate; in chronic hepatitis, IgG antibodies and markers of viral persistence predominate.
Clinically, acute hepatitis typically presents with more intense symptoms and more pronounced elevation of transaminases, while chronic hepatitis may be asymptomatic or oligosymptomatic with discretely elevated or fluctuating enzymes. The presence of fibrosis or hepatic cirrhosis generally indicates chronicity and is not expected in true acute phase.
Other important differentiations include: autoimmune hepatitis (positive autoimmune markers, absence of viral markers), drug-induced hepatitis (history of exposure to hepatotoxic medications, absence of viral markers), and alcoholic hepatitis (characteristic enzyme pattern with AST>ALT, history of significant alcohol consumption).
Step 4: Required documentation
Adequate documentation to support code 1E50 must mandatorily include: date of symptom onset or estimated date of exposure, detailed description of symptoms present, laboratory test results with dates (aminotransferases, bilirubin, prothrombin time, albumin), and results of specific serological tests that confirm viral etiology.
Additionally, the following should be documented: exposure history (travel, contact with known case, occupational exposure, injection drug use, blood transfusion, medical procedures), absence of other causes of hepatitis (hepatotoxic medications, significant alcohol consumption), and severity assessment including presence or absence of signs of liver failure.
For coding and follow-up purposes, it is essential to record: whether it is the first episode or recurrence, presence of relevant comorbidities, prior vaccination against hepatitis A and B, and follow-up plan to confirm resolution or detect chronicity. This complete documentation ensures accurate coding and facilitates continuity of care.
6. Complete Practical Example
Clinical Case
A 28-year-old previously healthy patient seeks medical care with a complaint of five days of intense fatigue, nausea, loss of appetite, and progressive jaundice. He reports that three days ago he noticed darkened urine and lighter-colored stools than usual. He denies fever, intense abdominal pain, or pruritus. He does not use regular medications, denies alcohol consumption, and has no history of previous liver disease.
In the epidemiological history, the patient mentions having returned four weeks ago from travel to a region with poor sanitary conditions, where he consumed water and food of questionable origin. He denies intravenous drug use, recent tattoos, occupational exposure to blood or blood products, and had no unprotected sexual relations during this period.
On physical examination, the patient appears in good general condition, lucid and oriented, icteric (++/4+), without signs of encephalopathy. Normal cardiopulmonary auscultation. Flat abdomen, palpable liver 2 cm below the right costal margin, normal consistency, mildly tender on palpation, without signs of peritoneal irritation. Spleen not palpable. Absence of ascites, collateral circulation, or other stigmata of chronic liver disease.
Laboratory Evaluation
Complete blood count: leukocytes 6,800/mm³ (without left shift), hemoglobin 14.2 g/dL, platelets 185,000/mm³. Liver function: ALT 1,450 U/L (normal up to 40), AST 1,120 U/L (normal up to 40), total bilirubin 7.8 mg/dL (direct 6.2 mg/dL, indirect 1.6 mg/dL), alkaline phosphatase 180 U/L, gamma-GT 145 U/L. Synthetic function: albumin 3.8 g/dL, prothrombin time 14 seconds (INR 1.2), without significant coagulopathy.
Viral serology: Anti-HAV IgM reactive, Anti-HAV IgG non-reactive, HBsAg non-reactive, Anti-HBc total non-reactive, Anti-HCV non-reactive, Anti-HEV IgM non-reactive. Abdominal ultrasound: liver of normal dimensions, regular contours, homogeneous parenchyma without signs of fibrosis or cirrhosis, non-dilated bile ducts, gallbladder without alterations, spleen of normal size.
Diagnostic Reasoning
The patient presents with a typical clinical picture of acute hepatitis: subacute onset of constitutional symptoms (fatigue, nausea, anorexia) followed by jaundice, dark urine, and acholic stools. The epidemiological history of recent travel to an endemic area with consumption of potentially contaminated water and food is compatible with fecal-oral transmission, characteristic of hepatitis A virus.
Laboratory findings confirm acute hepatitis: marked elevation of aminotransferases (hepatocellular pattern with ALT>AST), hyperbilirubinemia with direct predominance (cholestatic), and preserved synthetic function (normal albumin, mild coagulopathy). The positive serology for anti-HAV IgM confirms acute infection with hepatitis A virus, while negative serology for other hepatotropic viruses excludes coinfections.
The absence of stigmata of chronic liver disease on physical examination and normal ultrasound confirm this is an acute process in a previously healthy liver. There are no signs of hepatic insufficiency (no encephalopathy, significant coagulopathy, or ascites), characterizing acute hepatitis of mild to moderate severity.
Step-by-Step Coding
Criteria analysis: The patient meets all criteria for acute viral hepatitis: (1) clinical presentation compatible with acute hepatitic syndrome of recent onset, (2) significant elevation of transaminases with hepatocellular pattern, (3) serological confirmation of acute viral infection (positive anti-HAV IgM), (4) duration less than six months, (5) absence of other causes of hepatitis.
Code selected: 1E50 - Acute viral hepatitis
Complete justification: Code 1E50 is the most appropriate because it precisely documents the patient's condition: hepatitis caused by virus (hepatitis A) in its acute phase. This is not chronic hepatitis (1E51) because the infection is recent and virus A does not chronify. There is no severe acute hepatic insufficiency that would justify a specific code for this complication. It is not liver disease of another etiology.
Applicable complementary codes: Depending on the coding system and need for specificity, one may add: code for jaundice if symptom coding is required, Z code for history of travel to endemic area if relevant for epidemiological surveillance, and code to specify acute hepatitis A if more specific subcategories are available in the local system.
Follow-up plan: Document that patient requires outpatient follow-up with clinical and laboratory reassessment in two weeks to confirm trend toward resolution, counseling on transmission and prevention, relative rest, adequate diet, and immediate return if signs of hepatic insufficiency develop (mental confusion, bleeding, ascites).
7. Related Codes and Differentiation
Within the Same Category
1E51: Chronic viral hepatitis
The differentiation between acute viral hepatitis (1E50) and chronic hepatitis (1E51) is fundamental and is based primarily on temporal criteria and serological markers. Acute hepatitis is characterized by infection lasting less than six months, generally more intense symptoms, marked elevation of transaminases (frequently above 10-20 times the upper limit), and presence of acute infection markers (IgM antibodies).
On the other hand, chronic hepatitis is defined by persistence of viral infection for six months or more, which may be asymptomatic or oligosymptomatic, with normal, mildly elevated, or fluctuating transaminases, and markers of chronic infection (IgG antibodies, persistence of viral antigens such as HBsAg, persistent detection of HCV-RNA). Chronic hepatitis may present with progressive hepatic fibrosis and progress to cirrhosis, findings not expected in true acute phase.
Clinically, code 1E50 is used for the initial episode of viral hepatitis in the first six months, when it is still unknown whether there will be resolution or chronicity. If after six months there is persistence of viral markers or evidence of active infection, the code should be changed to 1E51. Some viruses (hepatitis A and E) practically never become chronic in immunocompetent individuals, while hepatitis B becomes chronic in approximately 5% of adults and hepatitis C in up to 85% of cases.
Differential Diagnoses
Autoimmune hepatitis: May present acutely similar to viral hepatitis, but differs by the presence of autoantibodies (ANA, anti-smooth muscle, anti-LKM), hypergammaglobulinemia, absence of viral markers, and frequently response to immunosuppression. It can occur at any age, with predominance in young women.
Drug-induced hepatitis: Various medications can cause acute hepatitis with clinical and laboratory presentation indistinguishable from viral hepatitis. Differentiation is based on detailed history of use of hepatotoxic medications (acetaminophen, anti-inflammatory drugs, antibiotics, antituberculous drugs, herbal remedies), temporal relationship between exposure and symptoms, absence of viral markers, and improvement after discontinuation of the causative agent.
Alcoholic hepatitis: Presents characteristic enzymatic pattern with AST typically two to three times higher than ALT (AST/ALT ratio >2), elevation of gamma-GT, history of heavy and prolonged alcohol consumption, and absence of viral markers. It may coexist with viral hepatitis in some cases.
Ischemic hepatitis: Caused by hepatic hypoperfusion (shock, severe heart failure), characterized by very marked and transient elevation of transaminases (frequently above 1,000-2,000 U/L), clinical context of hemodynamic instability, and rapid resolution after correction of the cause.
8. Differences with ICD-10
In ICD-10, acute viral hepatitis was coded in category B15-B19, with specific codes for each viral type: B15 for acute hepatitis A, B16 for acute hepatitis B, B17 for other acute viral hepatitis (including C, D, and E), B18 for chronic viral hepatitis, and B19 for unspecified viral hepatitis.
The main change in ICD-11 is the structural reorganization of viral hepatitis, with greater integration between acute and chronic forms within the same hierarchical category. Code 1E50 in ICD-11 groups all acute viral hepatitis, regardless of the etiologic agent, in a main code, with the possibility of additional specification through subcategories or extensions.
This change reflects a more clinical and practical approach, where initial recognition of acute hepatitis is the first step, followed by identification of the specific agent. In clinical practice, this facilitates initial coding when serological results are still pending, allowing coding as acute viral hepatitis and subsequently specifying the type when confirmed.
The practical impact includes greater flexibility in coding, better alignment with actual clinical practice, facilitation of epidemiological studies that evaluate acute hepatitis as a group, and reduction of coding errors related to premature specification of the etiologic agent before complete laboratory confirmation. Professionals should familiarize themselves with this new structure to ensure adequate transition and data comparability between systems.
9. Frequently Asked Questions
How is acute viral hepatitis diagnosed?
The diagnosis of acute viral hepatitis requires an integrated approach combining clinical, laboratory, and serological evaluation. Clinically, the physician seeks characteristic symptoms such as jaundice, fatigue, nausea, abdominal pain, dark urine, and acholic stools, in addition to relevant epidemiological history (blood exposure, travel to endemic areas, contact with known cases). Initial laboratory tests include aminotransferase dosage (ALT and AST), bilirubin, alkaline phosphatase, and liver function tests (albumin, prothrombin time). Etiological confirmation requires specific serological tests: anti-HAV IgM for hepatitis A, HBsAg and anti-HBc IgM for hepatitis B, RNA-HCV for acute hepatitis C, and anti-HEV IgM for hepatitis E. In selected cases, liver biopsy may be necessary, although it is rarely required in the acute phase.
Is treatment available in public health systems?
The treatment of acute viral hepatitis varies according to the etiological agent and severity of the condition. For hepatitis A and E, which are self-limited in most cases, treatment is mainly supportive (rest, hydration, adequate diet, avoiding hepatotoxins) and is universally available. For acute hepatitis B, most cases resolve spontaneously, but severe cases or those at risk of chronicity may require antivirals, which are generally available in public health systems. Acute hepatitis C may benefit from early antiviral treatment with direct-acting antivirals, whose availability varies among different health systems, although it has expanded significantly in recent years. Severe cases with acute liver failure may require intensive care and, rarely, emergency liver transplantation, available in specialized centers.
How long does treatment and recovery take?
The duration of treatment and recovery varies according to the type of hepatitis and severity of the condition. In hepatitis A, complete recovery generally occurs in 4 to 8 weeks, without need for specific treatment beyond supportive measures. Hepatitis E has a similar course, except in pregnant women where it can be more severe. In acute hepatitis B, most immunocompetent adults recover spontaneously in 3 to 6 months; when antiviral treatment is indicated, it may last 6 to 12 months. Acute hepatitis C, if treated, requires 8 to 12 weeks of direct-acting antivirals. During the acute phase, relative rest is recommended, avoiding alcohol and hepatotoxic medications, and regular medical follow-up with laboratory tests every 2 to 4 weeks until normalization. Return to normal activities is generally possible when symptoms improve and transaminases begin to decline.
Can this code be used in medical certificates?
Yes, code 1E50 can and should be used in official medical documentation, including medical certificates, when appropriate. In certificates for work or study leave, it is common to use the description "acute viral hepatitis" without necessarily specifying the etiological agent, protecting patient privacy while providing adequate medical justification for the leave. The duration of leave varies according to the severity and type of hepatitis, ranging from 2 to 8 weeks or more in severe cases. It is important that the documentation be accurate for purposes of epidemiological surveillance and compulsory notification, when applicable. In some contexts, it may be necessary to provide more detailed information for occupational health or insurance purposes, always respecting medical confidentiality and obtaining patient consent when appropriate.
Does acute viral hepatitis always cause jaundice?
No, acute viral hepatitis does not always cause visible jaundice. Many cases, especially in children and young adults, may be anicteric (without apparent jaundice) or oligosymptomatic, presenting only fatigue, malaise, and discrete laboratory alterations. It is estimated that only 30 to 50% of adults with hepatitis A develop jaundice, and an even smaller proportion in children. In acute hepatitis B, jaundice occurs in approximately 30% of cases. Acute hepatitis C is frequently asymptomatic or with minimal symptoms, rarely causing jaundice. The absence of jaundice does not exclude the diagnosis; confirmation is based on elevation of transaminases and positive serological markers. Anicteric cases often go unnoticed, being diagnosed incidentally on routine tests or screening.
What is the difference between acute hepatitis and fulminant hepatitis?
Acute hepatitis refers to the hepatic inflammatory process of recent onset caused by viruses, which in most cases evolves to complete recovery. Fulminant hepatitis (or severe acute liver failure) is a rare but potentially fatal complication of acute hepatitis, characterized by rapid development of severe liver failure with hepatic encephalopathy in a patient without prior liver disease, typically occurring within 8 weeks of symptom onset. It manifests with severe coagulopathy (INR >1.5), encephalopathy (confusion, drowsiness, coma), intense jaundice, and frequently multiple organ failure. Fulminant hepatitis requires urgent intensive care and may require emergency liver transplantation. Hepatitis B, D, and E viruses (especially in pregnant women) are more common causes, while hepatitis A rarely causes fulminance except in patients with prior liver disease.
Is isolation necessary for patients with acute viral hepatitis?
Precautions vary according to the type of hepatitis and route of transmission. For hepatitis A and E (fecal-oral transmission), enteric precautions are recommended: rigorous hand hygiene, use of separate sanitary facilities when possible, avoiding preparing food for others, and care with disposal of feces and contaminated materials. The patient may remain at home, hospitalization not being necessary except in severe cases. For hepatitis B, C, and D (blood and sexual transmission), social isolation is not necessary, but standard precautions are recommended: not sharing sharp objects (razors, toothbrushes), condom use, avoiding blood donation, and informing healthcare professionals about the diagnosis. Children with hepatitis A should be kept away from daycare and schools during the acute phase. Healthcare professionals with acute viral hepatitis are generally temporarily removed from care activities during the symptomatic phase.
Can someone who had acute viral hepatitis develop chronic hepatitis?
The risk of chronicity depends fundamentally on the type of virus causing acute hepatitis. Hepatitis A and E never become chronic in immunocompetent individuals, always evolving to complete cure. Acute hepatitis B becomes chronic in approximately 5% of immunocompetent adults, but this risk increases significantly in neonates (90%), infants (30-50%), and immunosuppressed individuals. Hepatitis C has a high rate of chronicity, with 70 to 85% of acute cases evolving to chronic infection if not treated early. Hepatitis D (Delta) only occurs in the presence of hepatitis B, and may become chronic when there is coinfection or superinfection. Factors associated with higher risk of chronicity include young age at infection, immunosuppression, coinfections, and severity of the acute condition. Follow-up after acute hepatitis is essential to detect early chronicity, allowing timely therapeutic intervention.
Keywords: Acute viral hepatitis, ICD-11 1E50, hepatitis coding, acute hepatitis A, acute hepatitis B, acute hepatitis C, viral hepatitis diagnosis, elevated transaminases, jaundice, hepatitis serological markers, differentiation acute chronic hepatitis.
External References
This article was prepared based on reliable scientific sources:
- 🌍 WHO ICD-11 - Acute viral hepatitis
- 🔬 PubMed Research on Acute viral hepatitis
- 🌍 WHO Health Topics
- 📋 CDC - Centers for Disease Control
- 📊 Clinical Evidence: Acute viral hepatitis
- 📋 Ministry of Health - Brazil
- 📊 Cochrane Systematic Reviews
References verified on 2026-02-03